サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1397516

抗体治療薬の世界市場：形態別、疾患領域別、投与経路別、エンドユーザー別、地域別、競合情勢-分析と予測（2024年～2033年）

Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033
出版日: | 発行: BIS Research | ページ情報: 英文 137 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
抗体治療薬の世界市場：形態別、疾患領域別、投与経路別、エンドユーザー別、地域別、競合情勢-分析と予測（2024年～2033年）
出版日: 2023年12月20日
発行: BIS Research
ページ情報: 英文 137 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗体治療薬市場は、バイオ医薬品およびライフサイエンス分野の中でも極めて重要な役割を担っており、医療および研究領域で多様な用途に使用される抗体の製造、進歩、商品化に専念しています。

これらの抗体（免疫グロブリン）は、免疫系によって生成される必須タンパク質であり、有害な病原体、毒素、異物を識別し、中和するために極めて重要です。市場においては、抗体は、診断、治療、研究、病気の検出や治療、研究室での実験や医薬品開発など、さまざまな目的のために生産、改変、応用されています。

世界の抗体治療薬市場の拡大は、いくつかの有力な要因によって推進されました。主に、慢性疾患の有病率の上昇と標的治療に対する需要の高まりが、革新的な治療法の探求を強めています。

当レポートでは、世界の抗体治療薬市場について調査し、市場の概要とともに、形態別、疾患領域別、投与経路別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

  • 動向：現在および将来の影響評価
  • サプライチェーンの概要
  • 研究開発レビュー
  • 規制状況
  • 主要な世界的出来事の影響分析- COVID-19
  • 市場力学の概要

第2章 用途

  • 用途のセグメンテーション
  • 用途の概要
  • 世界の抗体治療薬市場（疾患領域別）
  • 世界の抗体治療薬市場（投与経路別）
  • 世界の抗体治療薬市場（エンドユーザー別）

第3章 製品

  • 製品のセグメンテーション
  • 製品概要
  • 世界の抗体治療薬市場
  • 世界の抗体治療薬市場（形態別）

第4章 地域

  • 地域別の概要
  • 促進要因と抑制要因
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第5章 市場-競合ベンチマーキングと企業プロファイル

  • 今後の有力企業
  • 地理的評価
    • Hoffmann-La Roche Ltd.
    • AbbVie, Inc
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Regeneron Pharmaceuticals Inc.
    • Novartis AG
    • AstraZeneca
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
    • Takeda Pharmaceutical Company Ltd.
    • Abcam Plc.
    • Thermo Fisher Scientific, Inc
    • Cell Signaling Technology

第6章 調査手法

図表

List of Figures

  • Figure 1: Global Antibody Therapeutic Market, by region, 2022, 2026, and 2033
  • Figure 2: Pricing/Cost Analysis by Region, Supply Chain
  • Figure 3: Global Antibody Therapeutic Market, by Format, 2022, 2026, and 2033
  • Figure 4: Global Antibody Therapeutic Market, by Disease Area, 2022, 2026, and 2033
  • Figure 5: Global Antibody Therapeutic Market, by Route of Administration, 2022, 2026, and 2033
  • Figure 6: Global Antibody Therapeutic Market, by End User, 2022, 2026, and 2033
  • Figure 7: Global Antibody Therapeutic Market, Recent Developments
  • Figure 8: Supply chain and Identifying Risks within the Supply Chain
  • Figure 9: Global Antibody Therapeutic Market, 2022, 2026, and 2023
  • Figure 10: Global Antibody Therapeutic Market, 2022, 2026, and 2026
  • Figure 11: Impact Analysis of Market Navigating Factors
  • Figure 12: U.S. Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 13: U.S. Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 14: Canada Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 15: Canada Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 16: Germany Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 17: Germany Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 18: U.K. Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 19: U.K. Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 20: France Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 21: France Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 22: Rest of Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 23: Rest of Europe Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 24: China Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 25: China Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 26: Japan Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 27: Japan Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 28: India Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 29: India Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 30: Rest-of-Asia-Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 31: Rest-of-Asia-Pacific Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 32: Latin America Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 33: Latin America Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 34: The Middle East and Africa Antibody Therapeutic Market, By Disease Area ($ Million), 2022,2026, and 2033
  • Figure 35: The Middle East and Africa Antibody Therapeutic Market, By End-User ($ Million), 2022, 2026, and 2033
  • Figure 36: Strategic Initiatives, 2020 - 2023
  • Figure 37: Share of Strategic Initiatives
  • Figure 38: Data Triangulation
  • Figure 39: Top-Down and Bottom-Up Approach
  • Figure 40: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Antibody Therapeutic Market, Opportunity
  • Table 3: Global Antibody Therapeutic Market, by Product, $Million, 2022-2033
  • Table 4: Antibody Therapeutic Market, By Region, ($ Million), 2022-2033
  • Table 5: North America Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 6: North America Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 7: North America Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 8: U.S. Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 9: U.S. Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 10: Canada Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 11: Canada Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 12: Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 13: Europe Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 14: Europe Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 15: Germany Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 16: Germany Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 17: U.K. Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 18: U.K. Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 19: France Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 20: France Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 21: Rest of Europe Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 22: Rest of Europe Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 23: Asia Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 24: Asia Pacific Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 25: Asia Pacific Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 26: China Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 27: China Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 28: Japan Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 29: Japan Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 30: India Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 31: India Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 32: India Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 33: Rest-of-Asia-Pacific Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 34: Rest-of-Asia-Pacific Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 35: Rest-of-the-World Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 36: Rest-of-the-World Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 37: Rest-of-the-World Antibody Therapeutic Market, By Format ($ Million), 2022-2033
  • Table 38: Latin America Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 39: Latin America Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 40: The Middle East and Africa Antibody Therapeutic Market, By Disease Area ($ Million), 2022-2033
  • Table 41: The Middle East and Africa Antibody Therapeutic Market, By End User ($ Million), 2022-2033
  • Table 42: Market Share
目次
Product Code: BHL1660SA

“Global Antibody Therapeutic Market Poised for Remarkable Growth.”

The global antibody therapeutic market occupies a pivotal role within the biopharmaceutical and life sciences sectors, dedicated to the manufacturing, advancement, and commercialization of antibodies with diverse applications in medical and research domains. These antibodies, or immunoglobulins, are essential proteins generated by the immune system, crucial for identifying and neutralizing harmful pathogens, toxins, and foreign substances. Within the market context, antibodies are produced, modified, and applied for a spectrum of purposes, encompassing diagnostics, therapeutics, and research endeavors, spanning disease detection and treatment to laboratory experiments and pharmaceutical development.

The expansion of the global antibody therapeutic markets was propelled by several influential factors. Primarily, the rising prevalence of chronic diseases and the escalating demand for targeted therapies have intensified the quest for innovative treatment modalities.

Market Segmentation:

Segmentation 1: by Disease Area

  • Autoimmune and Inflammatory Disease
  • Oncology
  • Haematology
  • Infectious Disease
  • Osteology
  • Immunology
  • Neurology
  • Others Disease Area

Segmentation 2: by Route of Administration

  • Intravenous
  • Subcutaneous
  • Others Route of Administration

Segmentation 3: by End-User

  • Hospitals
  • Long term Care Facilities
  • Others End-User

Segmentation 4: by Format

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Antibody Fragments
  • Bispecific Antibodies
  • Others Novel Antibody Therapies

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

Key Questions Answered:

  • What are the growth opportunities for new entrants in the global antibody therapeutic sector?
  • Who are the primary players operating within the global antibody therapeutics market?
  • What key strategies are likely to be embraced by participants aiming to expand their share in the global antibody therapeutic industry?
  • How is the competitive landscape shaping up in the global antibody therapeutics market?
  • What emerging trends might impact the growth of the global antibody therapeutics market?
  • Which product type segment is anticipated to demonstrate a substantial CAGR in the future?
  • Which application segment is poised to capture a significant share in the global antibody therapeutic industry?
  • Which region presents lucrative opportunities for manufacturers in the global antibody therapeutics market?

Table of Contents

Executive Summary

1. Markets

  • 1.1. Trends: Current and Future Impact Assessment
    • 1.1.1. Sample Text
    • 1.1.2. Trend 1
    • 1.1.3. Trend 2
    • 1.1.4. Trend 3
  • 1.2. Supply chain Overview
    • 1.2.1. Value Chain Analysis
    • 1.2.2. Market Map
  • 1.3. Research and Development Review
    • 1.3.1. Patent Filing Trend (by Country, Company)
  • 1.4. Regulatory Landscape
  • 1.5. Impact Analysis for Key Global Events- COVID-19
  • 1.6. Market Dynamics Overview
    • 1.6.1. Market Drivers
    • 1.6.2. Market Restraints
    • 1.6.3. Market Opportunities

2. Application

  • 2.1. Application Segmentation
  • 2.2. Application Summary
  • 2.3. Global Antibody Therapeutic Market (By Disease Area)
    • 2.3.1. Autoimmune and Inflammatory Disease
    • 2.3.2. Oncology
    • 2.3.3. Haematology
    • 2.3.4. Infectious Disease
    • 2.3.5. Osteology
    • 2.3.6. Immunology
    • 2.3.7. Neurology
    • 2.3.8. Others Disease Area
  • 2.4. Global Antibody Therapeutic Market (By Route of Administration)
    • 2.4.1. Intravenous
    • 2.4.2. Subcutaneous
    • 2.4.3. Others Route of Administration
  • 2.5. Global Antibody Therapeutic Market (By End-User)
    • 2.5.1. Hospitals
    • 2.5.2. Long term Care Facilities
    • 2.5.3. Others End-User

3. Products

  • 3.1. Product Segmentation
  • 3.2. Product Summary
  • 3.3. Global Antibody Therapeutic Market
    • 3.3.1. Market Overview
      • 3.3.1.1. Analyst View
  • 3.4. Global Antibody Therapeutic Market (By Format)
    • 3.4.1. Monoclonal Antibodies
    • 3.4.2. Polyclonal Antibodies
    • 3.4.3. Antibody Fragments
    • 3.4.4. Bispecific Antibodies
    • 3.4.5. Others Novel Antibody Therapies

4. Regions

  • 4.1. Regional Summary
  • 4.2. Drivers and Restraints
  • 4.3. North America
    • 4.3.1. Regional Overview
    • 4.3.2. Driving Factors for Market Growth
    • 4.3.3. Factors Challenging the Market
    • 4.3.4. Application
    • 4.3.5. Product
    • 4.3.6. U.S.
    • 4.3.7. U.S. Antibody Therapeutic Market by Application
    • 4.3.8. Canada
    • 4.3.9. Canada Antibody Therapeutic Market by Application
  • 4.4. Europe
    • 4.4.1. Regional Overview
    • 4.4.2. Driving Factors for Market Growth
    • 4.4.3. Factors Challenging the Market
    • 4.4.4. Application
    • 4.4.5. Product
    • 4.4.6. Germany
    • 4.4.7. Germany Antibody Therapeutic Market by Application
    • 4.4.8. U.K.
    • 4.4.9. U.K. Antibody Therapeutic Market by Application
    • 4.4.10. France
    • 4.4.11. France Antibody Therapeutic Market by Application
    • 4.4.12. Rest of Europe
    • 4.4.13. Rest of Europe Antibody Therapeutic Market by Application
  • 4.5. Asia Pacific
    • 4.5.1. Regional Overview
    • 4.5.2. Driving Factors for Market Growth
    • 4.5.3. Factors Challenging the Market
    • 4.5.4. Application
    • 4.5.5. Product
    • 4.5.6. China
    • 4.5.7. China Antibody Therapeutic Market by Application
    • 4.5.8. Japan
    • 4.5.9. Japan Antibody Therapeutic Market by Application
    • 4.5.10. India
    • 4.5.11. India Antibody Therapeutic Market by Application
    • 4.5.12. Rest-of-Asia-Pacific
    • 4.5.13. Rest-of-Asia-Pacific Antibody Therapeutic Market by Application
  • 4.6. Rest-of-the-World (RoW)
    • 4.6.1. Regional Overview
    • 4.6.2. Driving Factors for Market Growth
    • 4.6.3. Factors Challenging the Market
    • 4.6.4. Application
    • 4.6.5. Product
    • 4.6.6. Latin America
    • 4.6.7. Latin America Antibody Therapeutic Market by Application
    • 4.6.8. The Middle East and Africa
    • 4.6.9. The Middle East and Africa Antibody Therapeutic Market by Application

5. Markets - Competitive Benchmarking & Company Profiles

  • 5.1. Next Frontiers…..
  • 5.2. Geographic Assessment
    • 5.2.1. Hoffmann-La Roche Ltd.
      • 5.2.1.1. Overview
      • 5.2.1.2. Top Products / Product Portfolio
      • 5.2.1.3. Top Competitors
      • 5.2.1.4. Target Customers
      • 5.2.1.5. Key Personnel
      • 5.2.1.6. Analyst View
      • 5.2.1.7. Market Share
    • 5.2.2. AbbVie, Inc
      • 5.2.2.1. Overview
      • 5.2.2.2. Top Products / Product Portfolio
      • 5.2.2.3. Top Competitors
      • 5.2.2.4. Target Customers
      • 5.2.2.5. Key Personnel
      • 5.2.2.6. Analyst View
      • 5.2.2.7. Market Share
    • 5.2.3. Amgen Inc.
      • 5.2.3.1. Overview
      • 5.2.3.2. Top Products / Product Portfolio
      • 5.2.3.3. Top Competitors
      • 5.2.3.4. Target Customers
      • 5.2.3.5. Key Personnel
      • 5.2.3.6. Analyst View
      • 5.2.3.7. Market Share
    • 5.2.4. Bristol-Myers Squibb Company
      • 5.2.4.1. Overview
      • 5.2.4.2. Top Products / Product Portfolio
      • 5.2.4.3. Top Competitors
      • 5.2.4.4. Target Customers
      • 5.2.4.5. Key Personnel
      • 5.2.4.6. Analyst View
      • 5.2.4.7. Market Share
    • 5.2.5. Johnson & Johnson Services, Inc.
      • 5.2.5.1. Overview
      • 5.2.5.2. Top Products / Product Portfolio
      • 5.2.5.3. Top Competitors
      • 5.2.5.4. Target Customers
      • 5.2.5.5. Key Personnel
      • 5.2.5.6. Analyst View
      • 5.2.5.7. Market Share
    • 5.2.6. Merck & Co., Inc.
      • 5.2.6.1. Overview
      • 5.2.6.2. Top Products / Product Portfolio
      • 5.2.6.3. Top Competitors
      • 5.2.6.4. Target Customers
      • 5.2.6.5. Key Personnel
      • 5.2.6.6. Analyst View
      • 5.2.6.7. Market Share
    • 5.2.7. Regeneron Pharmaceuticals Inc.
      • 5.2.7.1. Overview
      • 5.2.7.2. Top Products / Product Portfolio
      • 5.2.7.3. Top Competitors
      • 5.2.7.4. Target Customers
      • 5.2.7.5. Key Personnel
      • 5.2.7.6. Analyst View
      • 5.2.7.7. Market Share
    • 5.2.8. Novartis AG
      • 5.2.8.1. Overview
      • 5.2.8.2. Top Products / Product Portfolio
      • 5.2.8.3. Top Competitors
      • 5.2.8.4. Target Customers
      • 5.2.8.5. Key Personnel
      • 5.2.8.6. Analyst View
      • 5.2.8.7. Market Share
    • 5.2.9. AstraZeneca
      • 5.2.9.1. Overview
      • 5.2.9.2. Top Products / Product Portfolio
      • 5.2.9.3. Top Competitors
      • 5.2.9.4. Target Customers
      • 5.2.9.5. Key Personnel
      • 5.2.9.6. Analyst View
      • 5.2.9.7. Market Share
    • 5.2.10. Eli Lilly and Company
      • 5.2.10.1. Overview
      • 5.2.10.2. Top Products / Product Portfolio
      • 5.2.10.3. Top Competitors
      • 5.2.10.4. Target Customers
      • 5.2.10.5. Key Personnel
      • 5.2.10.6. Analyst View
      • 5.2.10.7. Market Share
    • 5.2.11. GlaxoSmithKline plc.
      • 5.2.11.1. Overview
      • 5.2.11.2. Top Products / Product Portfolio
      • 5.2.11.3. Top Competitors
      • 5.2.11.4. Target Customers
      • 5.2.11.5. Key Personnel
      • 5.2.11.6. Analyst View
      • 5.2.11.7. Market Share
    • 5.2.12. Takeda Pharmaceutical Company Ltd.
      • 5.2.12.1. Overview
      • 5.2.12.2. Top Products / Product Portfolio
      • 5.2.12.3. Top Competitors
      • 5.2.12.4. Target Customers
      • 5.2.12.5. Key Personnel
      • 5.2.12.6. Analyst View
      • 5.2.12.7. Market Share
    • 5.2.13. Abcam Plc.
      • 5.2.13.1. Overview
      • 5.2.13.2. Top Products / Product Portfolio
      • 5.2.13.3. Top Competitors
      • 5.2.13.4. Target Customers
      • 5.2.13.5. Key Personnel
      • 5.2.13.6. Analyst View
      • 5.2.13.7. Market Share
    • 5.2.14. Thermo Fisher Scientific, Inc
      • 5.2.14.1. Overview
      • 5.2.14.2. Top Products / Product Portfolio
      • 5.2.14.3. Top Competitors
      • 5.2.14.4. Target Customers
      • 5.2.14.5. Key Personnel
      • 5.2.14.6. Analyst View
      • 5.2.14.7. Market Share
    • 5.2.15. Cell Signaling Technology
      • 5.2.15.1. Overview
      • 5.2.15.2. Top Products / Product Portfolio
      • 5.2.15.3. Top Competitors
      • 5.2.15.4. Target Customers
      • 5.2.15.5. Key Personnel
      • 5.2.15.6. Analyst View
      • 5.2.15.7. Market Share

6. Research Methodology

  • 6.1. Data Sources
    • 6.1.1. Primary Data Sources
    • 6.1.2. Secondary Data Sources
    • 6.1.3. Data Triangulation
  • 6.2. Market Estimation and Forecast